scholarly journals ENZYMATIC DEGRADATION OF CROSS-LINKED EXCIPIENT MATRIX OF CO-PROCESSED XANTHAN GUM-AMYLOSE AND DISSOLUTION PROFILE OF DICLOFENAC SODIUM TABLET

2017 ◽  
Vol 9 ◽  
pp. 77
Author(s):  
Silvia Surini ◽  
Nurul Nizma ◽  
Azizahwati Azizahwati
Keyword(s):  
Sustained Release ◽  
Xanthan Gum ◽  
Enzymatic Degradation ◽  
Diclofenac Sodium ◽  
Alpha Amylase ◽  
Dissolution Profile ◽  
Sustained Release Tablet ◽  
Sustained Release Tablets ◽  
Single Matrix ◽  
Release Tablet

Objectives: This study aims to determine the amount of excipient that is degraded by alpha-amylase and the influence of alpha-amylase to thedissolution profile of sustained-release tablets that use matrix CL-Co-A-XG.Methods: Excipient is cross-linked with two concentrations of sodium trimetaphospate, which are 6% (CL6-Co-A-XG) and 12% (CL12-Co-A-XG).Each excipient is made with the ratios 1:1, 1:2, and 2:1 amylose-xanthan gum. Enzymatic degradation tests are performed on excipient powders for60 minutes. Sustained-release tablet with CL-Co-A-XG excipient as a matrix is formulated through direct compression method. Then, drug dissolutiontests are performed in a phosphate buffer with a pH of 7.4 both using and without using alpha-amylase as a medium for 8 hrs.Results: The results of this study show that CL6-Co-A-XG and CL12-Co-A-XG degraded 20% at 10 and 30 minutes, respectively. In addition, the releaseprofile of F1-F6 tablets show the sustained-release profile that follows zero-order and Korsmeyer–Peppas kinetics and is unaffected by the presenceof alpha-amylase.Conclusions: From this study, it can be concluded that the CL-Ko-A-XG excipients are more resistant to enzymatic degradation than amylose. Therefore,this excipient shows potential as a single matrix sustained-release tablet.

scholarly journals Formulation Development and Evaluation of Diclofenac Sodium Sustained Release Tablet Using Factorial Design.

2015 ◽  
Vol 5 (3) ◽  
pp. 1528-1538
Author(s):  
Sanjay P. Aher . ◽  
Rohidas S. Patil . ◽  
Harshal A. Sonje . ◽  
Avish D. Maru . ◽  
Rajendra K. Surwase .
Keyword(s):  
Sustained Release ◽  
Factorial Design ◽  
Diclofenac Sodium ◽  
Formulation Development ◽  
Sustained Release Tablet ◽  
Release Tablet

Sustained release tablet formulation of diethylcarbamazine. Part II

1985 ◽  
Vol 24 (2-3) ◽  
pp. 355-358 ◽  
Author(s):  
S.K. Baveja ◽  
K.V. Ranga Rao ◽  
Rajinder Kumar ◽  
K. Padmalatha Devi
Keyword(s):  
Sustained Release ◽  
Tablet Formulation ◽  
Sustained Release Tablet ◽  
Release Tablet

DESIGN DEVELOPMENT AND OPTIMIZATION OF A SUSTAINED RELEASE TABLET OF BOSENTAN MONOHYDRATE FOR PULMONARY ARTERIAL HYPERTENSION

INDIAN DRUGS ◽  
2019 ◽  
Vol 56 (03) ◽  
pp. 61-67
Author(s):  
P. P Dighe ◽  
H. M Tank ◽  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Sustained Release ◽  
Arterial Hypertension ◽  
In Vitro Release ◽  
Design Development ◽  
23 Factorial Design ◽  
Sustained Release Tablet ◽  
Pulmonary Arterial ◽  
Release Tablet

Pulmonary arterial hypertension (PAH) means high blood pressure in the lungs caused by obstruction in the small arteries of the lungs.The current study involves the fabrication of oral matrix sustained release tablet of bosentan monohydrate, a dual endothelin receptor antagonist, the optimisation of its in vitro release and characterisation. Methocel K4M PremiumDC2, a directly compressible HPMC grade, has been used as the sustained release polymer. Pregelatinised starch is used as a diluent and release modifier and sodium lauryl sulphate as a solubiliser. The influence of the above variables on drug release is measured using a 23 factorial design using design expert software. Surface response plots show significant interaction among the formulation variables, thus aiding in optimization of bilayer tablet.

Sign in / Sign up

Export Citation Format

Share Document